Health knowledge made personal
Join this community!
› Share page:
Search posts:

A New Class of Broad-spectrum Antibiotics: Naturally-occurring Chrysophaetins and Their Analogues

Posted Feb 21 2012 7:00pm

Description of Invention:
This invention, offered for licensing and commercial development, relates to a new class of naturally occurring antimicrobial compounds called Chrysophaetins, and to their synthetic analogues. Isolated from an alga species, the mechanism of action of these compounds is through the inhibition of bacterial cytoskeletal protein FtsZ, an enzyme necessary for the replication of bacteria. FtsZ is responsible for Z-ring assembly in bacteria, which leads to bacterial cell division. Highly conserved among all bacteria, FtsZ is a very attractive antimicrobial target.

The chrysophaetin exhibits antimicrobial activity against drug resistant bacteria, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE), as well as other drug susceptible strains. The general structure of the natural compound is shown below:

General structure of the natural compound

  • Therapeutic potential for treating general and drug-resistant bacterial infections in clinical and veterinary populations.
  • Antiseptics in hospital settings.

  • Effective for commonly occurring drug-resistant infections MRSA and VRE.
  • Broad spectrum of efficacy because mechanism of action is against the bacterial protein FtsZ, which has similar structure in all bacteria.
  • Potential for additive efficacy when combined with other antibiotics due to distinct mechanism of action.
  • Other drugs with similar structure and antibacterial properties can be synthesized using the chemical structure template shown above.

Development Status:
  • Early-stage
  • In vitro data available

Carole A Bewley Clore (NIDDK)

Patent Status:
HHS, Reference No. E-116-2010/0
PCT, Application No. PCT/US2011/026220 filed 25 Feb 2011

Relevant Publication:
  1. Plaza A, et al. [ PMID 20536175 ]

Collaborative Research Opportunity:
The National Institute of Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic Chemistry, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the chrysophaentin antibiotics. Please contact Marguerite J. Miller at 301-451-3636 or for more information.

For Licensing Information Please Contact:
John Stansberry Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-5236
Fax: 301-402-0220

Ref No: 2374

Updated: 02/2012

Post a comment
Write a comment:

Related Searches